Data from Vaxart oral COVID-19 vaccine phase I study suggested broad cross-reactivity against Coronaviruses
On May 3, 2021, Vaxart announced that new data obtained from its Phase I COVID-19 trial added to…
Precipio launched Rapid COVID-19 Antibody test on Amazon platform
On May 3, 2021, Precipio announced that it had successfully launched its COVID-19 rapid antibody test (20 minute)…
Moderna announced supply agreement with Gavi for up to 500 million doses of COVID-19 Vaccine Moderna for COVAX
On May 3, 2021, Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up to 500…
Novavax initiated pediatric expansion for phase 3 clinical trial of COVID-19 vaccine
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
Gavi signed agreement with Moderna to secure doses on behalf of COVAX Facility
On May 3, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Moderna…
Moderna announced Emergency Use listing granted by the WHO for its COVID-19 vaccine
On Apr. 30, 2021, Moderna announced that the World Health Organization (WHO) had issued Emergency Use Listing (EUL)…
Lonza and Moderna entered agreement to double drug substance production for COVID-19 vaccine in Visp
On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance…
COVID-19 | Life Science News | NIH | Vaccine
NIH announced investment of $29 million to address COVID-19 disparities
On Apr. 29, 2021, the National Institutes of Health announced it was funding $29 million in additional grants…
Large collaboration created cell atlas of COVID-19 pathology
On Apr. 29, 2021, scientists from several hospitals and research centers reported what happens in individual cells of…
Moderna announced an increased global supply for COVID-19 vaccine to up to 3 billion doses in 2022
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
VBI Vaccines announced publication of Challenge Study Data of its eVLP vaccine candidate against COVID-19
On Apr. 28, 2021, VBI Vaccines announced that preclinical data of VBIﾒs enveloped virus-like particle (eVLP) vaccine candidate,…
Innovation Pharma surpassed 50 percent enrollment in phase 2 clinical trial of Brilacidin for COVID-19
On Apr. 28, 2021, Innovation Pharma announced that enrollment had surpassed 50 percent of the total targeted number…
Fully vaccinated adults 65 and older are 94% less likely to be hospitalized with COVID-19
On Apr. 28, 2021, the Centers for Disease Control and Prevention (CDC) announced that both mRNA COVID-19 vaccines…
Merck announced licensing agreements with Indian manufacturers to expand access to molnupiravir for treatment of COVID-19
On Apr. 27, 2021, Merck announced the company had entered into non-exclusive voluntary licensing agreements for molnupiravir with…
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | Life Science History | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | USDA | Vaccine | WHO
COVID-19 science and reason
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
Gilead Sciences announced steps to expand availability of Remdesivir in India
On Apr. 26, 2021, Gilead Sciences announced that in response to the rapid increase in COVID-19 cases in…
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile…
COVID-19 vaccine responses studied in people with immune deficits
On Apr. 23, 2021, the NIH announced that a study assessing how people with immune system deficiencies or…
COVID-19 infections survey revealed significant reductions in COVID-19 infections with single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
On Apr. 23, 2021, University of Oxford data from the COVID-19 Infection Survey was the first to show…
FDA and CDC lifted recommended pause on Johnson & Johnson COVID-19 vaccine
On Apr. 23, 2021, following a thorough safety review, including two meetings of the CDCﾒs Advisory Committee on…
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients began
On Apr. 22, 2021, the NIH announced that a phase 3 trial to test the safety and efficacy…
Relief and AdVita announced initiation of phase 2 trial with inhaled RLF-100 for prevention of COVID-19-related ARDS
On Apr. 22, 2021, RELIEF THERAPEUTICS and AdVita Lifescience announced that the first patient was expected to be…
The WHO announced continued review of emerging evidence on AstraZeneca COVID-19 vaccines
On Apr. 22, 2021, the Strategic Advisory Group of Experts (SAGE) on Immunization annouced updated interim guidance on…
Quidel signed retail distribution agreement to increase access to at-home COVID-19 testing
On Apr. 22, 2021, Quidel announced that it had completed a distribution and fulfillment agreement with McKesson to…
FDA completed inspection of Emergent BioSolutions vaccine production facility
On Apr. 21, 2021, the FDA announced that it had completed an inspection of the Emergent BioSolutions and…
XPhyto signed German distribution, storage and logistics agreement for 25-minute COVID-19 PCR test
On Apr. 21, 2021, XPhyto announced that it had entered into an agreement with an established German pharmaceutical…
Valneva initiated pivotal phase 3 clinical trial for inactivated, COVID-19 vaccine using Dynavax’s CpG 1018ﾙ adjuvant
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
Trevena announced TRV027 selected for study in global REMAP-CAP trial in COVID-19 patients
On Apr. 21, 2021,Trevena announced that TRV027, the Companyﾒs novel AT1 receptor selective agonist, had been selected for…
Large NIH clinical trial tested polyclonal antibody therapeutic for COVID-19
On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal…